论文部分内容阅读
目的探讨辛伐他汀联用氢氯吡格雷对急性冠脉综合征患者高敏C-反应蛋白(hs-CRP)及血脂的影响。方法将117例急性冠脉综合征患者分为辛伐他汀常规治疗组(48例)和辛伐他汀联用氢氯吡格雷组(69例)。观察治疗后6周两组血浆hs-CRP和血脂含量的变化。结果两组患者治疗后6周血浆hs-CRP、血脂水平均显著下降(P<0.01),但辛伐他汀联用氢氯吡格雷组的hs-CRP下降幅度较辛伐他汀组更大(P<0.05),两组血脂改善情况比较差异无统计学意义(P>0.05)。结论辛伐他汀联用氢氯吡格雷应用于急性冠脉综合征患者能更有效地降低血浆hs-CRP浓度,更有利于抑制炎症、稳定斑块。
Objective To investigate the effect of simvastatin combined with clopidogrel on high-sensitivity C-reactive protein (hs-CRP) and serum lipids in patients with acute coronary syndrome. Methods One hundred and seventy-one patients with acute coronary syndrome were divided into routine simvastatin treatment group (n = 48) and simvastatin plus hydrochloropirimine treatment group (n = 69). The changes of plasma hs-CRP and blood lipid levels in both groups were observed 6 weeks after treatment. Results The levels of plasma hs-CRP and blood lipid decreased significantly (P <0.01) 6 weeks after treatment in both groups, but the reduction of hs-CRP in simvastatin group and hydroclopagine group was larger than that of simvastatin group <0.05). There was no significant difference between the two groups in the improvement of blood lipids (P> 0.05). Conclusion Simvastatin combined with clopidogrel in patients with acute coronary syndrome can reduce plasma hs-CRP concentration more effectively, and more conducive to inhibiting inflammation and stabilizing plaque.